Track topics on Twitter Track topics that are important to you
Floragenex, a genomics testing service provider focused on next-generation DNA sequencing, will become a wholly owned subsidiary of point-of-care diagnostics developer Sedia Biosciences, the companies said today, through a merger whose value was not disclosed. The merger is designed to create a combined provider of genomic services for scientific customers as well as testing solutions for human immunodeficiency virus (HIV) and other infectious agents. Sedia, founded in 2009, develops and commercializes point-of-care diagnostics in HIV and other human diseases. Roger Gale, Sedia’s Chairman and CEO, said in a statement that the merger “will strengthen and diversify our scientific capability across both immuno and molecular (DNA) diagnostic technologies, broaden our potential product range, expand access to the plant and animal kingdom markets, accelerate development of next-generation products, and strengthen sales and marketing, business development, and strategic planning.” “The merger will also yield many synergies and benefits in ...
Original Article: Floragenex, Sedia Biosciences MergeNEXT ARTICLE
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...